stethoscope

Join our network and find credentialing information.

Log in to Availity Essentials™ to access patient benefits, claims information and more.

Find tools and materials to support doing business with us.

Learn more about research and trends that impact your practice.

Find self-service info and phone numbers and update your provider data.

Review prior authorization lists for services, medications and submission guidance.

Prior authorization submission information

Professionally administered drugs prior authorization

Find appeals guidelines and payment policy information.

Learn how to submit claims and find coding guidance.

Find policies for procedures, devices and medications.

Review guidelines and health programs to support your patients and practice.

Find dental benefits, tools and resources.

Prior authorization for professionally administered drugs 

Locate state-specific resources for Humana Healthy Horizons® (Medicaid).

compass

Shop plans, learn about Medicare and explore member resources.

Search for in-network medical, vision, dental and pharmacy providers.

Drug recall notice for Ruzurgi (amifampridine) 10 mg tablets

A couple researching a prescription online

To assist you in the care of your patients, we would like to alert you to the recall of three lots of Ruzurgi® (amifampridine) 10 mg tablets on Sept. 13, 2021.1 We recommend you review your medical records and contact all patients for whom you have prescribed this medication to warn them of the recall. 

The drug manufacturer, Jacobus Pharmaceutical Company Inc., is voluntarily recalling three lots of this drug, which is prescribed as treatment for Lambert-Eaton myasthenic syndrome (LEMS). The drugs are being recalled because they were found to be contaminated with yeast, mold and aerobic bacteria. Patients with LEMS who receive these drugs may have an increased risk for serious and life-threatening infections due to their underlying condition.

Other lot numbers of Ruzurgi that are not affected by this recall are available.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

Information for providers:1

    We have sent a letter to your Humana-covered patients who have had a claim for Ruzurgi and asked them to contact their physicians or healthcare providers if their medication is included in the recall and if they have experienced problems that may be related to using these drug products. 

    Healthcare professionals with questions regarding this recall can contact Jacobus Pharmaceutical Company Inc. by phone at 609-799-8221, ext. 2120, Monday – Friday, 9 a.m. – 5 p.m., Eastern time.

    Patients may report adverse reactions or quality problems experienced with the use of this product to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.            Online: Complete and submit the        report.                    Select “Consumer/Patient (FDA Form 3500B).”



        Regular mail or fax: Download the        form.                    Select “Form FDA 3500B – Voluntary Reporting for Consumers” and submit by mail to the address on the form or by fax to 800-FDA-0178 (332-0178).







    “Jacobus Pharmaceutical Company Inc. Issues Voluntary Worldwide Recall of Ruzurgi® (amifampridine) 10 mg Tablets Due to Yeast, Mold, and Bacterial Contamination,” U.S. Food and Drug Administration, last accessed Sept. 21, 2021, www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/jacobus-pharmaceutical-company-inc-issues-voluntary-worldwide-recall-ruzurgir-amifampridine-10-mg?utm_medium=email&utm_source=govdelivery. 



Drug recall notice for Nature-Throid and WP Thyroid tablets

Drug recall notice for Belviq, Belviq XR (lorcaserin)

Drug recall notice for NP Thyroid tablets

Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension

Formulary changes for generic Ventolin HFA

Impact of ongoing angiotensin II receptor blocker drug recalls

Product name	NDC number	Lot number	Expiration date
Ruzurgi 10 mg	4993811001	18038	03/2023
Ruzurgi 10 mg	4993811001	18039	03/2023
Ruzurgi 10 mg	4993811001	18079	05/2023

Reference:

Pharmacy news